Granegis (Granisetron)

Granegis is an oral medication that contains the active ingredient granisetron, a selective 5‑HT3 receptor antagonist used as an antiemetic. It is marketed in the European Union and is available by prescription only. Granegis works by blocking serotonin receptors in the central and peripheral nervous system, helping to prevent nausea and vomiting associated with chemotherapy and postoperative recovery. It is prescribed for adult patients under medical supervision.

Granegis is indicated for the prevention and treatment of nausea and vomiting in specific clinical situations.

- Chemotherapy‑induced nausea and vomiting (CINV) in adult patients. - Acute and delayed phases of CINV following moderately or highly emetogenic chemotherapy. - Postoperative nausea and vomiting (PONV) after surgical procedures requiring general anesthesia. - Nausea and vomiting associated with radiation therapy when combined with chemotherapy. - Off‑label use may include nausea related to gastrointestinal disorders, as determined by a physician. - Prevention of nausea in patients receiving highly emetogenic chemotherapy regimens.

The safety profile of Granegis includes both common, generally mild reactions that are often transient and rare, potentially serious events that require prompt medical evaluation.

Common: - Headache – mild to moderate intensity. - Constipation – reduced bowel movements. - Diarrhea – loose stools. - Fatigue – feeling of tiredness. - Dizziness – light‑headed sensation. - Nausea – occasional mild nausea. - Dry mouth – reduced salivation. - Abdominal discomfort – mild cramps.

Serious: - Severe allergic reaction – anaphylaxis, swelling of face or throat. - Cardiac arrhythmia or QT prolongation – irregular heartbeat or changes on ECG. - Serotonin syndrome – agitation, tremor, hyperthermia when used with serotonergic drugs.

Before initiating Granegis, healthcare providers should assess patient history and consider specific precautions to minimize risks.

- Assess for known hypersensitivity to granisetron or other 5‑HT3 antagonists. - Use caution in patients with a history of cardiac conduction disorders or prolonged QT interval. - Evaluate renal and hepatic function, especially in severe impairment, as dosage adjustment may be needed. - Consider potential pregnancy or breastfeeding status; discuss risks with a qualified professional. - Review concomitant medications that may affect serotonin levels or cardiac rhythm. - Monitor for signs of severe constipation or bowel obstruction during therapy.

Granegis may interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid: - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol, linezolid) that could increase risk of serotonin syndrome. - Medications known to prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics, fluoroquinolones). - Concomitant use with other antiemetics that have overlapping mechanisms, which may increase adverse effects.

Use with caution: - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) which may raise granisetron plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine) which may reduce effectiveness. - Anticholinergic drugs that could exacerbate constipation. - Use with caution in patients taking diuretics, as electrolyte disturbances may affect cardiac rhythm.